FDA Approves ZONTIVITY™ (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease
Dateline City:
WHITEHOUSE STATION, N.J.
ZONTIVITY Added to Standard of Care Demonstrated Long-Term Benefit Through Three Years
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK),
known as MSD outside the United States and Canada, today announced that
the U.S. Food and Drug Administration (FDA) has approved ZONTIVITY™
(vorapaxar) for the reduction of thrombotic cardiovascular events in
patients with a history of heart attack (myocardial infarction) or in
patients with narrowing of leg arteries, called peripheral arterial
disease (PAD).
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orPatrick Witmer, 267-305-4910orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
More News: Cardiology | Cardiovascular | Food and Drug Administration (FDA) | Heart | Heart Attack | Merck | Pharmaceuticals